- Triggered by achieving the initial enrollment target in trial sites in Latin America, Summit Therapeutics (SMMT -5.2%) has earned a $1M milestone payment from licensee Eurofarma Laboratórios SA related to lead candidate ridinilazole for the treatment of Clostridium difficile (C. diff) infection.
- The studies are comparing the small molecule antibiotic to standard-of-care vancomycin.
Summit Therapeutics earn $1M milestone on advancement of ridinilazole
Recommended For You
About SMMT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SMMT | - | - |
Summit Therapeutics Inc. |